CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.
FactSnippet No. 1,225,716 |
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.
FactSnippet No. 1,225,716 |
CSL Limited was founded in 1916 as the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture.
FactSnippet No. 1,225,717 |
In 1928, CSL Limited became involved in antivenene manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute.
FactSnippet No. 1,225,719 |
CSL Limited completed an initial public offering in June 1994 at A$2.
FactSnippet No. 1,225,720 |
In 2000, CSL Limited doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG.
FactSnippet No. 1,225,721 |
CSL Limited was the second Australian public company to have reached a share price of over $100 per share.
FactSnippet No. 1,225,722 |
In June 2020 CSL Limited announced it would exercise its right to acquire Vitaeris.
FactSnippet No. 1,225,724 |
On 7 September 2020, CSL Limited signed agreements with the Australian government to supply the University of Queensland vaccine and to manufacture the Oxford University vaccine, which would yield nearly 85 million doses for Australians.
FactSnippet No. 1,225,726 |